We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Serum Albumin Level Predicts Serious HIV Events

By LabMedica International staff writers
Posted on 18 Jan 2018
Print article
Image: A digitally colorized scanning electron microscopic (SEM) photograph depicting a single, red-colored H9-T-cell that had been infected by numerous, spheroid-shaped, mustard-colored human immunodeficiency virus (HIV) particles, which can be seen attached to the cell\'s surface membrane (Photo courtesy of the US National Institute of Allergy and Infectious Diseases).
Image: A digitally colorized scanning electron microscopic (SEM) photograph depicting a single, red-colored H9-T-cell that had been infected by numerous, spheroid-shaped, mustard-colored human immunodeficiency virus (HIV) particles, which can be seen attached to the cell\'s surface membrane (Photo courtesy of the US National Institute of Allergy and Infectious Diseases).
Serum albumin may be used to stratify human immunodeficiency virus (HIV)–infected persons with a high CD4+ T-cell count according to their risk of serious non-Acquired Immune Deficiency Syndrome (AIDS) endpoints.

Serum albumin is sampled in many clinical settings, and previous literature has suggested that low amounts of it are associated with HIV-related comorbidities like inflammation, liver disease and nephropathy and lower serum albumin levels are strongly predictive of mortality risk, particularly within one year.

Scientists at the University Hospital Rigshospitalet (Copenhagen, Denmark) and their colleagues tested serum albumin as a disease marker, and assessed data from the Strategic Timing of Antiretroviral Treatment (START) study, which was conducted between 2009 and 2013. The team included baseline serum albumin measures from 4,576 patients, who represented 98% of START participants, and assessed treatment outcomes. Serious non-AIDS events were defined as cardiovascular disease, end-stage renal disease, liver disease, non-AIDS-defining cancer, death from any of those conditions, and death not related to AIDS, accident or violence.

The investigators found that in all, 71 patients had serious non-AIDS events, 63 had AIDS events and 788 were hospitalized. A higher baseline serum albumin level per 1 g/dL was associated with a decreased risk for serious non-AIDS events and for hospitalization. It was not associated with a risk for AIDS. Similar results were obtained in a time-updated model, after controlling for interleukin 6, and after excluding initial follow-up years. Serum albumin was independently associated with hospitalization but not with risk of AIDS.

Andreas Ronit, MD, of the University of Copenhagen department of infectious diseases and the lead author of the study, said, “We found that lower serum albumin was a strong predictor of serious non-AIDS events and hospitalization in seemingly healthy HIV-infected persons, with high CD4 counts. These associations were independent of traditional risk factors and various laboratory measures.” The study was published on December 13, 2017, in The Journal of Infectious Diseases.

Related Links:
University Hospital Rigshospitalet

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
Xylazine Immunoassay Test
Xylazine ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: Liquid biopsy could detect and monitor aggressive small cell lung cancer (Photo courtesy of Shutterstock)

Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer

Small cell lung cancer (SCLC) is a highly aggressive type of cancer known for its ability to metastasize. The behavior of tumors is largely governed by which genes are turned on, or transcribed, irrespective... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The groundbreaking treatment approach has shown promise in hard-to-treat cancers (Photo courtesy of 123RF)

Genetic Testing Combined With Personalized Drug Screening On Tumor Samples to Revolutionize Cancer Treatment

Cancer treatment typically adheres to a standard of care—established, statistically validated regimens that are effective for the majority of patients. However, the disease’s inherent variability means... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.